Abstract Library

#4235 Tricuspid valve replacement and liver transplantation in a 51-year-old female patient with grade 1 ileum NET and refractory carcinoid syndrome

Introduction: Refractory carcinoid syndrome (RCSy) could lead to severe complications.

Conference:

Presenting Author: Tőke J

Authors: Tőke J, Kövesdi A, Szolnoky J, Huszty G, Piros L,

Keywords: refractory carcinoid syndrome, liver transplantation, ileum neuroendocrine tumor,

#3819 Dosimetry evaluation in 177Lu-labeled somatostatin receptor analogue therapy

Introduction: Dosimetry reporting in patients receiving PRRT is fundamental to ensure the safety and efficacy of treatment.

Conference:

Presenting Author:

Authors: Cichoński A, Kempińska-Wróbel M, Kolasińska-Ćwikła A, Zrajkowska A, Szarowicz A,

Keywords: radionuclide therapy, dosimetry, lutetium,

#3524 Correlation of loss of ATRX expression with scintigraphic imaging studies in pancreatic neuroendocrine neoplasms

Introduction: Somatic inactivating mutations of ATRX (α thalassemia/mental retardation syndrome X-linked) in pancreatic neoplasms (pNENs) are associated with aggressive phenotype and are considered an independent prognostic factor of poor overall survival.

Conference:

Presenting Author:

Authors: Tsoli M, Kyriakopoulos G, Daskalakis K, Chatziioannou S, Alevroudis E,

Keywords: ATRX, somatostatin receptor scintigraphy, FDG-PET/CT,

#3351 Safety and efficacy of peptide receptor radionuclide therapy with 177 Lu-DOTA 0-Tyr 3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors

Introduction: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA0-Tyr3-octreotate (177Lu-DOTATATE) is one of the most reliable treatments for unresectable, progressive neuroendocrine tumors (NETs) with somatostatin receptor expression.

Conference:

Presenting Author:

Authors: Kobayashi N, Takano S, Ito K, Sugiura M, Ogawa M,

Keywords: Peptide receptor radionuclide therapy, 177Lu-DOTA0-Tyr3-octreotate, neuroendocrine tumor,

#3344 Somatostatin receptor scintigraphy in pancreatic neuroendocrine tumor

Introduction: Pancreatic neuroendocrine tumors (PNET) are rare tumors, but their incidence is increasing. They are characterised by a high rate of metastasis (50%), mainly to the liver. Due to their relatively slow tumor growth, they are associated with prolonged survival rates. Somatostatin receptor scintigraphy (SRS) is a valuable tool for diagnostic, staging and follow-up.

Conference:

Presenting Author:

Authors: Borsali M, Ridouh M, Medjahdi A,

Keywords: pancreatic net, tektrotyd scan, metastasis,